Advanced Nuclear Medicine Ingredients
Radiometals labeled radiopharmaceuticals and a global service provider in the radiopharmaceutical field. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
AUD9m (Public information from Nov 2018)
Liège Liège (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | <1m | 1.0m | 3.0m | 3.0m | 7.0m |
| % growth | - | 25 % | 200 % | - | 133 % |
| EBITDA | (<1m) | (<1m) | (<1m) | (1.0m) | 1.0m |
| % EBITDA margin | (63 %) | (40 %) | (3 %) | (33 %) | 14 % |
| Profit | (<1m) | (<1m) | <1m | (<1m) | 3.0m |
| % profit margin | (25 %) | (20 %) | 17 % | (10 %) | 43 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
€5.2m Valuation: €5.2m 5.2x EV/LTM Revenues -13.0x EV/LTM EBITDA | Acquisition | ||
| Total Funding | - | ||
Related Content
Recent News about Advanced Nuclear Medicine Ingredients
EditMore about Advanced Nuclear Medicine Ingredients
EditANMI SA is a pharmaceutical company developing innovative radiopharmaceutical solutions and a global service provider in the nuclear medicine field, located in Liège, Belgium. ANMI has developed innovative solutions to facilitate the scalable synthesis of “theranostic” radiopharmaceuticals and to ease their daily production in hospitals and radiopharmacies. ANMI's vision is focused on increasing patient access to new highly specific theranostic radiopharmaceuticals through streamlined and cost-effective production processes.